These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 2844543)

  • 1. Graft versus host disease after transfusions of non-irradiated blood cells in patients having received autologous bone marrow. A report of 4 cases following ablative chemotherapy for solid tumors.
    Postmus PE; Mulder NH; Elema JD
    Eur J Cancer Clin Oncol; 1988 May; 24(5):889-94. PubMed ID: 2844543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic hematopoietic stem cell transplantation in ovarian carcinoma: results of five patients.
    Bay JO; Fleury J; Choufi B; Tournilhac O; Vincent C; Bailly C; Dauplat J; Viens P; Faucher C; Blaise D
    Bone Marrow Transplant; 2002 Jul; 30(2):95-102. PubMed ID: 12132048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autologous cryopreserved platelets and prophylaxis of bleeding in autologous bone marrow transplantation.
    van Imhoff GW; Arnaud F; Postmus PE; Mulder NH; Das PC; Smit Sibinga CT
    Blut; 1983 Oct; 47(4):203-9. PubMed ID: 6311311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclophosphamide and VP 16-213 with autologous bone marrow transplantation. A dose escalation study.
    Postmus PE; de Vries EG; De Vries-Hospers HG; Vriesendorp R; van Imhoff GW; Holthuis JJ; Sibinga CT; Sleijfer DT; Mulder NH
    Eur J Cancer Clin Oncol; 1984 Jun; 20(6):777-82. PubMed ID: 6086355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential allogeneic graft-versus-tumor effect in a patient with ovarian cancer.
    Bay JO; Choufi B; Pomel C; Dauplat J; Durando X; Tournilhac O; Travade P; Plagne R; Blaise D
    Bone Marrow Transplant; 2000 Mar; 25(6):681-2. PubMed ID: 10734306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic stem cell transplantation as treatment for heavily treated, refractory acute graft-versus-host disease after HLA-mismatched stem cell transplantation.
    Ikegame K; Yoshihara S; Taniguchi Y; Kaida K; Inoue T; Okada M; Taniguchi K; Hasei H; Tamaki H; Fujioka T; Kato R; Soma T; Ogawa H
    Exp Hematol; 2011 Aug; 39(8):880-90. PubMed ID: 21689724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Graft versus host disease following transfusion of normal blood products to patients with malignancies.
    Kessinger A; Armitage JO; Klassen LW; Landmark JD; Hayes JM; Larsen AE; Purtilo DT
    J Surg Oncol; 1987 Nov; 36(3):206-9. PubMed ID: 3316850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy does not nullify the ability of donor lymphocyte infusions to mediate graft-versus-host reactions.
    Fuchs EJ; Seber A; Altomonte V; Braine HG; Humphrey RL; Jones RJ; Noga SJ; Schepers K; Wright SK; Vogelsang GB
    Bone Marrow Transplant; 1998 Aug; 22(3):303-5. PubMed ID: 9720749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute graft-versus-host disease of the heart.
    Roberts SS; Leeborg N; Loriaux M; Johnson FL; Huang ML; Stenzel P; Thiede C; Godder KT
    Pediatr Blood Cancer; 2006 Oct; 47(5):624-8. PubMed ID: 16206193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transfusions shortly before HLA-matched marrow transplantation for leukemia are associated with a decrease in chronic graft-versus-host disease.
    deGast GC; Beatty PG; Amos D; Mickelson EM; Sullivan KM; Anderson JE; Giblett ER; Appelbaum F; Storb R; Deeg HJ
    Bone Marrow Transplant; 1991 Apr; 7(4):293-5. PubMed ID: 2070135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [High dose chemotherapy with autologous bone marrow rescue for small cell lung cancer].
    Bao YH
    Zhonghua Zhong Liu Za Zhi; 1992 Nov; 13(6):452-5. PubMed ID: 1315671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic transplantation combining mobilized blood and bone marrow in patients with refractory hematologic malignancies.
    Nemunaitis J; Rosenfeld C; Collins R; Pallansch P; Piñeiro L; Ohr S; Waxman D; Stone M; Fay J; Miller W
    Transfusion; 1995 Aug; 35(8):666-73. PubMed ID: 7631407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of autologous bone marrow transplantation in various malignancies.
    Dicke KA; Jagannath S; Spitzer G; Poynton C; Zander A; Vellekoop L; Reading CL; Jehn UW; Tindle S
    Semin Hematol; 1984 Apr; 21(2):109-22. PubMed ID: 6330904
    [No Abstract]   [Full Text] [Related]  

  • 15. Autologous bone marrow transplantation following high-dose chemotherapy with cyclophosphamide, BCNU and VP-16 in small cell carcinoma of the lung and a review of current literature.
    Stahel RA; Takvorian RW; Skarin AT; Canellos GP
    Eur J Cancer Clin Oncol; 1984 Oct; 20(10):1233-8. PubMed ID: 6092092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case of transfusion-associated graft-versus-host disease not prevented by white cell-reduction filters.
    Akahoshi M; Takanashi M; Masuda M; Yamashita H; Hidano A; Hasegawa K; Kasajima T; Shimizu M; Motoji T; Oshimi K
    Transfusion; 1992 Feb; 32(2):169-72. PubMed ID: 1542924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination chemotherapy of intermediate-dose cytarabine, idarubicin, plus etoposide and subsequent mobilized donor leukocyte infusion for relapsed acute leukemia after allogeneic bone marrow transplantation.
    Lee JH; Lee KH; Kim S; Seol M; Kim SH; Kim WK; Lee JS
    Leuk Res; 2001 Apr; 25(4):305-12. PubMed ID: 11248327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors.
    Carnevale-Schianca F; Caravelli D; Gallo S; Coha V; D'Ambrosio L; Vassallo E; Fizzotti M; Nesi F; Gioeni L; Berger M; Polo A; Gammaitoni L; Becco P; Giraudo L; Mangioni M; Sangiolo D; Grignani G; Rota-Scalabrini D; Sottile A; Fagioli F; Aglietta M
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):459-466. PubMed ID: 28039079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased risk of lethal graft-versus-host disease-like syndrome after transplantation into NOD/SCID mice of human mobilized peripheral blood stem cells, as compared to bone marrow or cord blood.
    Gorin NC; Piantadosi S; Stull M; Bonte H; Wingard JR; Civin C
    J Hematother Stem Cell Res; 2002 Apr; 11(2):277-92. PubMed ID: 11983099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute graft-vs-host disease. Development following autologous and syngeneic bone marrow transplantation.
    Hood AF; Vogelsang GB; Black LP; Farmer ER; Santos GW
    Arch Dermatol; 1987 Jun; 123(6):745-50. PubMed ID: 3555353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.